ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Dynamic Coagulation Function Changes in COVID-19 Survivors With Coronary Artery Disease.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) and Coronavirus disease 2019 (COVID-19) are both associated with a hypercoagulable state, yet the long-term interaction between these prothrombotic conditions remains poorly characterized. This study investigated dynamic changes in coagulation function among COVID-19 survivors with CAD over a two-year follow-up period. A total of 117 CAD patients admitted to Shanghai Pudong Hospital between March and June 2022 were retrospectively enrolled: 60 with confirmed COVID-19 infection (COVID-19 group) and 57 without COVID-19 (control group). Thromboelastography (TEG) and conventional coagulation tests were performed at admission and at one and two years after discharge. Results showed that at one and two years after discharge, the COVID-19 group exhibited a comprehensive TEG profile indicative of a hypercoagulable state-including accelerated clot initiation, rapid propagation, and enhanced clot strength- compared to the control group (P < 0.05). In contrast, no significant between-group differences were observed in conventional coagulation parameters (P > 0.05). Notably, neutrophil levels in the COVID-19 group were significantly elevated at one and two years after discharge (P = 0.0353 and P = 0.0397, respectively) compared to acute-phase levels, while lymphocyte and platelet counts remained stable. Stratified analysis by antithrombotic intensity further revealed that standard antithrombotic regimens did not fully normalize the TEG-defined hypercoagulability in COVID-19 survivors at two-year follow-up. In conclusion, CAD patients with prior COVID-19 infection demonstrate sustained hypercoagulability and elevated neutrophil levels up to two years after discharge. These findings highlight the importance of TEG-based coagulation monitoring and neutrophil surveillance in CAD patients recovering from COVID-19 and support the need for individualized anticoagulation strategies. Future research should validate these findings in larger, multicenter cohorts and explore the underlying mechanisms and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.